心脉隆联合哌拉西林治疗慢性阻塞性肺疾病急性加重期患者的临床效果研究

Clinical study on Xinmailong and Piperacillin in treatment of acute exacerbation of chronic obstructive pulmonary disease

目的研究心脉隆联合哌拉西林治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)急性加重期患者的临床效果。方法选择2017年6月—10月我院呼吸科收治的慢性阻塞性肺疾病急性加重期患者80例,将其随机分为2组,每组40例,对照组给予哌拉西林治疗,观察给予心脉隆联合哌拉西林治疗。对比2组疗效、呼吸困难修正评分、血气指标及不良反应发生情况。结果观察组治疗总有效率(95.00%)较对照组(80.00%)高,差异有统计学意义(P<0.05);治疗后与对照组相比,观察组m MRC评分较低,差异有统计学意义(P<0.05);治疗后,观察组Pa O2、Sa O2水平较对照组高,Pa CO2水平较对照组低,差异有统计学意义(P<0.05);对照组局部红肿、恶心、呕吐、腹泻等不良反应总发生率略高,但与观察组相比,差异无统计学意义(P>0.05)。结论心脉隆联合哌拉西林治疗慢性阻塞性肺疾病急性加重期可有效提升疗效,在缓解患者呼吸困难症状的同时还可改善其血气指标,且安全性较高。

Objective To study the clinical effects of Xinmailong and piperacillin in treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods 80 AECOPD patients in the respiratory department from June 2017 to October 2017 were randomly divided into two groups, 40 cases in each group. Control group was given piperacillin, while observation group was treated with Xinmailong and piperacillin. The efficacy, revised dyspnea score, blood gas index, adverse reactions were compared between the two groups. Results The total effective rate of observation group （95.00%） was higher than control group （80.00%） （P〈0.05）; After treatment, the mMRC score of observation group was lower than that of control group （P〈0.05） ; After treatment, the levels of PaO2 and SaO2 in observation group were higher than those in control group, while the PaCO2 level was lower than control group （P〈0.05） ; The total incidence of local swelling, nausea, vomiting and diarrhea in control group （ 12.50% ） was slightly higher than observation group （ 10.00% ）, but there was no statistical difference （P〉0.05）.Conclusion Xinmailong and piperacillin in treatment of AECOPD can increase clinical effects, relieve dyspnea, improve blood gas indexes and have better safety.